News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to
View HTML
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2019 Results
Call scheduled for today, May 9, at 4:30pm ET TUCSON, Ariz. , May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9
TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2019 after the market close on
View HTML
Toggle Summary HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases
Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its
View HTML
Toggle Summary HTG Introduces the HTG EdgeSeq Mouse mRNA Tumor Response Panel
TUCSON, Ariz. , March 27, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Full Year 2018 Results
Revenue increased 46% in 2018 compared to the prior year reflecting continued success growing the company’s profiling business with Pharma company customers TUCSON, Ariz. , March 07, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a life science company whose mission
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on Thursday, March 7
TUCSON, Ariz. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter and year ended December 31, 2018 after the market close
View HTML
Toggle Summary HTG Molecular to Present Corporate Overview at the Cowen & Company 39th Annual Health Care Conference
TUCSON, Ariz. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th
View HTML
Toggle Summary HTG Molecular Announces an Amendment and Extension to its Precision Diagnostic Partnership (PDP) Two
TUCSON, Ariz. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its second precision diagnostic partnership program (“PDP Two”) with QIAGEN Manchester Limited
View HTML
Toggle Summary HTG Molecular to Present Corporate Overview at the 8th Annual SVB Leerink Global Healthcare Conference
TUCSON, Ariz. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview the 8 th Annual SVB Leerink
View HTML